178 related articles for article (PubMed ID: 29065189)
1. Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies.
Satoh D; Iwado S; Abe S; Kazuki K; Wakuri S; Oshimura M; Kazuki Y
PLoS One; 2017; 12(10):e0187072. PubMed ID: 29065189
[TBL] [Abstract][Full Text] [Related]
2. Development of Caco-2 cells expressing four CYPs via a mammalian artificial chromosome.
Ohta Y; Kazuki K; Abe S; Oshimura M; Kobayashi K; Kazuki Y
BMC Biotechnol; 2020 Aug; 20(1):44. PubMed ID: 32819341
[TBL] [Abstract][Full Text] [Related]
3. HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved.
Tolosa L; Gómez-Lechón MJ; Pérez-Cataldo G; Castell JV; Donato MT
Arch Toxicol; 2013 Jun; 87(6):1115-27. PubMed ID: 23397584
[TBL] [Abstract][Full Text] [Related]
4. Bioluminescence Measurement of Time-Dependent Dynamic Changes of CYP-Mediated Cytotoxicity in CYP-Expressing Luminescent HepG2 Cells.
Iwado S; Abe S; Oshimura M; Kazuki Y; Nakajima Y
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799598
[TBL] [Abstract][Full Text] [Related]
5. NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies.
Schulz C; Kammerer S; Küpper JH
Clin Hemorheol Microcirc; 2019; 73(1):249-260. PubMed ID: 31561354
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
7. Upgrading cytochrome P450 activity in HepG2 cells co-transfected with adenoviral vectors for drug hepatotoxicity assessment.
Tolosa L; Donato MT; Pérez-Cataldo G; Castell JV; Gómez-Lechón MJ
Toxicol In Vitro; 2012 Dec; 26(8):1272-7. PubMed ID: 22138474
[TBL] [Abstract][Full Text] [Related]
8. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.
Xuan J; Chen S; Ning B; Tolleson WH; Guo L
Chem Biol Interact; 2016 Aug; 255():63-73. PubMed ID: 26477383
[TBL] [Abstract][Full Text] [Related]
9. In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression.
Genovese S; Epifano F; Curini M; Menger D; Zembruski NC; Weiss J
Phytomedicine; 2011 May; 18(7):586-91. PubMed ID: 21112752
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells.
Westerink WM; Schoonen WG
Toxicol In Vitro; 2007 Dec; 21(8):1581-91. PubMed ID: 17637504
[TBL] [Abstract][Full Text] [Related]
11. Generation of HepG2 Cells with High Expression of Multiple Drug-Metabolizing Enzymes for Drug Discovery Research Using a PITCh System.
Negoro R; Tasaka M; Deguchi S; Takayama K; Fujita T
Cells; 2022 May; 11(10):. PubMed ID: 35626714
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.
Salminen KA; Meyer A; Jerabkova L; Korhonen LE; Rahnasto M; Juvonen RO; Imming P; Raunio H
Phytomedicine; 2011 Apr; 18(6):533-8. PubMed ID: 20851588
[TBL] [Abstract][Full Text] [Related]
13. Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database.
Sim SC; Ingelman-Sundberg M
Methods Mol Biol; 2013; 987():251-9. PubMed ID: 23475683
[TBL] [Abstract][Full Text] [Related]
14. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition.
Dahlinger D; Duechting S; Nuecken D; Sydow K; Fuhr U; Frechen S
J Pharmacol Toxicol Methods; 2016; 77():66-75. PubMed ID: 26528794
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Parent- and Metabolite-Induced Mitochondrial Toxicities Using CYP-Introduced HepG2 cells.
Takemura A; Gong S; Sato T; Kawaguchi M; Sekine S; Kazuki Y; Horie T; Ito K
J Pharm Sci; 2021 Sep; 110(9):3306-3312. PubMed ID: 34097978
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
18. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.
Turpeinen M; Tolonen A; Chesne C; Guillouzo A; Uusitalo J; Pelkonen O
Toxicol In Vitro; 2009 Jun; 23(4):748-53. PubMed ID: 19328226
[TBL] [Abstract][Full Text] [Related]
19. Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4.
Steinbrecht S; König R; Schmidtke KU; Herzog N; Scheibner K; Krüger-Genge A; Jung F; Kammerer S; Küpper JH
Toxicology; 2019 Jan; 412():37-47. PubMed ID: 30500380
[TBL] [Abstract][Full Text] [Related]
20. In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450.
Winitthana T; Niwattisaiwong N; Patarapanich C; Tantisira MH; Lawanprasert S
Toxicol In Vitro; 2011 Jun; 25(4):890-6. PubMed ID: 21349323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
